ContractExecutive Employment Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations • New York
This Third Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into on February 25, 2019, to be effective as of April 1, 2019 (the “Effective Date”), by and between Mylan Inc. (the “Company” or “Mylan”) and Rajiv Malik (“Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
This Executive Employment Agreement (the “Agreement”) is dated as of February 25, 2019, and effective as of April 1, 2019 (the “Effective Date”), by and between Mylan Inc. (the “Company” or “Mylan”) and Kenneth S. Parks (“Executive”).
AMENDMENT TO TERM CREDIT AGREEMENTTerm Credit Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations • New York
AMENDMENT dated as of February 22, 2019 (this “Amendment”), to the Term Credit Agreement, dated as of November 22, 2016 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among MYLAN N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands, with its corporate seat (statutaire zetel) in Amsterdam, the Netherlands and registered with the Dutch chamber of commerce under number 61036137 (the “Borrower”), certain Affiliates and Subsidiaries of the Borrower from time to time party thereto as Guarantors, each Lender from time to time party thereto (the “Lenders”) and GOLDMAN SACHS BANK USA, as Administrative Agent (the “Agent”).
November 3, 2018Executive Employment Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations
Reference is made to the Second Amended and Restated Executive Employment Agreement, entered into on February 25, 2014 and effective as of January 1, 2014 (the “Agreement”), by and between you and Mylan Inc. The parties hereto acknowledge and agree that the Term of Employment as set forth in Section 2 of the Agreement shall be extended to April 1, 2019. All other provisions of the Agreement, as modified by the foregoing, shall remain in full force and effect.
AMENDMENT TO REVOLVING CREDIT AGREEMENTRevolving Credit Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations • New York
AMENDMENT dated as of February 22, 2019 (this “Amendment”), to the Revolving Credit Agreement, dated as of July 27, 2018 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among MYLAN INC., a Pennsylvania corporation (the “Borrower”), MYLAN N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands, with its corporate seat (statutaire zetel) in Amsterdam, the Netherlands and registered with the Dutch chamber of commerce under number 61036137 (“Parent” and a “Guarantor”), certain Affiliates and Subsidiaries of Parent from time to time party thereto as Guarantors, each Lender from time to time party thereto (the “Lenders”), each Issuing Bank from time to time party thereto and BANK OF AMERICA, N.A., as Administrative Agent (the “Agent”).
November 3, 2018Executive Employment Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations
Reference is made to the Second Amended and Restated Executive Employment Agreement, entered into on February 25, 2014 and effective as of January 1, 2014 (the “Agreement”), by and between you and Mylan Inc. The parties hereto acknowledge and agree that the Term of Employment as set forth in Section 2 of the Agreement shall be extended to April 1, 2019. All other provisions of the Agreement, as modified by the foregoing, shall remain in full force and effect.
ContractExecutive Employment Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations • New York
This Third Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into on February 25, 2019, to be effective as of April 1, 2019 (the “Effective Date”), by and between Mylan Inc. (the “Company” or “Mylan”) and Heather Bresch (“Executive”).
CONSULTING AGREEMENTConsulting Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
This Consulting Agreement (“Agreement”) is made by and between Daniel M. Gallagher (“Gallagher”) and Mylan Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
